Here are the 10-K annual reports from Rezolute, Inc. (RZLT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RZLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RZLT filings page.
Rezolute, Inc. (RZLT) reported fiscal 2026 results and clinical updates for ersodetug, its investigational treatment for hypoglycemia associated with hyperinsulinism.
In congenital HI, Phase 3 sunRIZE did not meet its primary endpoint or key secondary endpoint at the Week 24 evaluable window. In September 2026, the FDA was still reviewing Rezolute’s submission to evaluate a potential regulatory path. In tumor HI, 7 of the initial 8 upLIFT participants met the responder criterion, defined as at least a 50 percent reduction from baseline in intravenous glucose requirements. The eighth withdrew before completing the pivotal treatment phase and is counted as a non-responder.
Rezolute recorded a net loss of approximately $77.6 million for fiscal 2026, compared with $74.4 million in fiscal 2025, and net cash used in operating activities was $64.6 million. At June 30, 2026, cash and equivalents plus marketable debt securities totaled $107.8 million. Management believes those resources are adequate to fund contractual obligations, ongoing trials and planned activities for at least 12 months from the financial statements’ issuance; additional equity or debt financing will be needed for all long-term liquidity requirements.
Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.
The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.